PNC Financial Services Group Inc. lowered its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 1.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 289,408 shares of the medical instruments supplier’s stock after selling 5,571 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Becton Dickinson and were worth $66,498,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently added to or reduced their stakes in BDX. IndexIQ Advisors LLC acquired a new position in Becton Dickinson and in the fourth quarter worth $25,000. Verus Capital Partners LLC acquired a new position in shares of Becton Dickinson and during the fourth quarter valued at $27,000. Pinnacle Financial Partners Inc. acquired a new position in shares of Becton Dickinson and during the fourth quarter valued at $31,000. Cedar Mountain Advisors LLC acquired a new position in shares of Becton Dickinson and during the fourth quarter valued at $42,000. Finally, Harwood Advisory Group LLC acquired a new position in shares of Becton Dickinson and during the first quarter valued at $50,000. 86.79% of the stock is owned by institutional investors and hedge funds.
Shares of BDX stock opened at $243.90 on Thursday. The stock’s fifty day moving average is $252.77 and its 200-day moving average is $255.49. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.66 and a current ratio of 0.98. The stock has a market capitalization of $71.37 billion, a PE ratio of 73.19, a PEG ratio of 2.82 and a beta of 0.95. Becton Dickinson and Co has a 52 week low of $197.75 and a 52 week high of $286.72.
Becton Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.55 EPS for the quarter, topping the consensus estimate of $2.32 by $0.23. The company had revenue of $4.25 billion for the quarter, compared to analysts’ expectations of $4.10 billion. Becton Dickinson and had a return on equity of 15.75% and a net margin of 6.10%. The business’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.59 earnings per share. As a group, analysts forecast that Becton Dickinson and Co will post 10.54 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 1.30%. The ex-dividend date is Monday, June 8th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.05%.
Several equities analysts have recently issued reports on BDX shares. Morgan Stanley reduced their price target on shares of Becton Dickinson and from $271.00 to $255.00 and set an “equal weight” rating for the company in a report on Friday, March 27th. UBS Group lifted their price objective on shares of Becton Dickinson and from $260.00 to $265.00 and gave the company a “neutral” rating in a research note on Friday, May 8th. Citigroup boosted their price target on shares of Becton Dickinson and from $234.00 to $260.00 and gave the stock a “neutral” rating in a research report on Friday, May 8th. Cfra dropped their price target on Becton Dickinson and from $285.00 to $278.00 and set a “hold” rating on the stock in a research note on Friday, May 8th. Finally, TheStreet cut Becton Dickinson and from a “b” rating to a “c+” rating in a research note on Monday, March 9th. Nine analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $275.79.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Further Reading: What is the accumulation/distribution indicator?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.